Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-Conjugated Tam-NHC-Gold(I) Complexes Overcome ESR1 Mutant Breast Cancer Resistance and Downregulate the RAMP3/CALCR Signaling Pathway.

Journal of medicinal chemistry - 23 Jul 2026

Lu Yunlong, Liu Lijuan, Liang Zhenlin, Schroder Wayne A, Wen Zhenfan, Zheng Tianpeng, Niu Ben, Xie Chunqi, Zhang He, Min Jian, Du Qianming, Liu Wukun

Abstract excerpt

Endocrine resistance remains a major obstacle in the effective treatment of hormone-receptor-positive breast cancer. ESR1 mutations, such as Y537S and D538G, are commonly considered to confer such resistance. It is necessary to develop novel therapeutic agents to overcome endocrine resistance. Herein, we developed drug-conjugated Tam-NHC-gold(I) complexes that can target breast cancer cells by the binding of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Drug Resistance, Neoplasm

Share to Estrogen Receptor alpha

Share to MCF-7 Cells

Share to Mice, Nude

Share to Tamoxifen

Source

Identifiers

PMID: 42378404
DOI: 10.1021/acs.jmedchem.5c02812

Genes

CALCR
ESR1
RAMP3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-Conjugated Tam-NHC-Gold(I) Complexes Overcome ESR1 Mutant Breast Cancer Resistance and Downregulate the RAMP3/CALCR Signaling Pathway.PMID 42378404Read ↗

Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.Semantic proximity Read ↗

Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality.Semantic proximity Read ↗

Pharmacologically regulated bioorthogonal stabilization domain for regulation of CAR T cellsSemantic proximity Read ↗

Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer.Semantic proximity Read ↗

Rhodacyanine Derivative Selectively Targets Cancer Cells and Overcomes Tamoxifen ResistanceSemantic proximity Read ↗

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast CancerSemantic proximity Read ↗

Half-sandwich Os( ii ) and Ru( ii ) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cellsSemantic proximity Read ↗

Targeting LINC00152 activates cAMP/Ca <sup>2+</sup> /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancerSemantic proximity Read ↗

Recurrent triple-negative breast cancer from cysteine deprivation loses tumorigenicity via downregulation of the CST4 signalingSemantic proximity Read ↗

Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compoundsSemantic proximity Read ↗

Cytotoxic Salan–Titanium(IV) Complexes: High Activity Toward a Range of Sensitive and Drug‐Resistant Cell Lines, and Mechanistic InsightsSemantic proximity Read ↗

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.